

Special Issue

Exosomes in Cancer Metastasis

Message from the Guest Editor

Since 1889, research on the mechanisms responsible for metastasis has been largely focused on interactions between the tumor and the host. Until the idea of extracellular vesicles as intercellular communication was put forward, new insights were gained into the mechanism of tumor metastasis. However, many unanswered questions exist. For one, we have no information about how tumor-derived EVs are directed to an organ and how exactly they arrive there.

Additionally, once at the site, how do the EVs engage specific tissue cells? Once engaged, which components of the exosome cargo, i.e., proteins, lipids or nucleic acids, delivered to recipient cells are responsible for inducing pro-metastatic changes? Can microvesicles (MVs) be more effective in shaping pre-metastatic changes than small EVs? Are the direct effects of tumor-derived EVs the only or the major pro-metastatic mechanism? Can the indirect interactions of EVs with immune or neural systems be involved in creating the pro-metastatic niche? Answering these questions is of prime importance for unraveling the complex mesh of molecular interactions that underlie metastasis.

Guest Editor

Prof. Dr. Theresa L. Whiteside

Cancer Center, Department of Pathology, University of Pittsburgh School of Medicine and UPMC Hillman, Pittsburgh, PA 15213, USA

Deadline for manuscript submissions

closed (31 March 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/181667

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)